Sarah A. Solomon

Sarah A. Solomon

Partner
Sarah A. Solomon

Sarah A. Solomon is a partner in the firm’s Technology & Life Sciences Group.

Ms. Solomon represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as co-development, joint research and development agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, distribution, supply, clinical trial, university licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and patent portfolio acquisitions). Ms. Solomon also counsels clients in connection with international transactions and relationships in North America, South America, Europe and Asia.

Experience

Strategic Alliances and Collaborations

  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease, with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • Moderna Therapeutics in strategic transactions with Merck, Alexion Pharmaceuticals and AstraZeneca with total upfront deal value in excess of $350 million, plus downstream payments
  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
  • Lycera in its collaboration with Merck valued over $300 million in total potential deal value
  • BIND Therapeutics in its strategic alliances with AstraZeneca, Pfizer and Amgen for up to $590 million in aggregate upfront and milestone payments to develop and commercialize Accurins™, a targeted and programmable cancer nanomedicine
  • Abide Therapeutics in its collaboration with Merck valued up to $430 million
  • Cephalon in its exclusive license agreement with Eagle Pharmaceuticals with a total deal value in excess of $120 million, plus royalties
  • Selecta Biosciences in its strategic global alliance with Sanofi-Aventis to develop immunotherapies for life-threatening allergies, with milestones up to $300 million per allergen indication, plus royalties
  • Unum Therapeutics in its strategic collaboration and license agreement with Seattle Genetics to develop and commercialize ACTR therapies for cancer, with a total potential deal value of over $640 million, plus royalties

M&A

  • Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
  • F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
  • ZOLL Medical in its sale to Asahi Kasei for $2.2 billion

Credentials

Education

J.D., 2001
University of California Hastings College Law
B.S., Biology, 1996
University of California, San Diego

Admissions

Bar

California
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers